Neovacs considers an exit from the stock market to optimize its assets

Biopharmaceutical company Neovacs is potentially planning to delist from the Paris Stock Exchange. The Board of Directors is currently evaluating options for this strategy. The goal is to overcome the financing difficulties observed in the financial markets for companies in the preclinical stage.

In parallel, Neovacs is preparing to create an unlisted subsidiary, Arnity, dedicated to the field of allergies. This approach aims to attract external investors and raise 20 million euros needed to advance clinical trials. An independent evaluation of the assets transferred to Arnity is underway.

Neovacs intends to refocus on its role as an investor in BioTech and MedTech companies, while continuing to exploit its intellectual property.